120 related articles for article (PubMed ID: 3500279)
1. Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin.
Schwartz CL; Minniti CP; Harwood P; Na S; Banquerigo ML; Strauss LC; Kurtzberg J; Smith SD; Civin CI
J Clin Oncol; 1987 Dec; 5(12):1900-11. PubMed ID: 3500279
[TBL] [Abstract][Full Text] [Related]
2. Combined chemoseparation and immunoseparation of clonogenic T lymphoma cells from human bone marrow using 2'-deoxycoformycin, deoxyadenosine, 3A1 monoclonal antibody, and complement.
Haleem A; Kurtzberg J; Olsen GA; Rhinehardt-Clark A; Leslie DS; Ray L; Smith CA; Peters WP; Haynes BF; Bast RC
Cancer Res; 1987 Sep; 47(17):4608-12. PubMed ID: 3113721
[TBL] [Abstract][Full Text] [Related]
3. The relative sensitivity of peripheral blood T-lymphocyte colony forming cells and bone marrow CFU-GM to deoxyadenosine and 2'deoxycoformycin.
Russell NH; Carron J; Hoffbrand AV; Bellingham AJ
Leuk Res; 1985; 9(2):315-9. PubMed ID: 3872974
[TBL] [Abstract][Full Text] [Related]
4. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
Ruers TJ; Buurman WA; van der Linden CJ
J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
[TBL] [Abstract][Full Text] [Related]
5. Preclinical studies on deoxycoformycin and deoxyadenosine as pharmacologic T cell purging tools.
Sheridan W; Gordon DS; Fullen AJ; Olson A; Vogler WR; Winton E
Bone Marrow Transplant; 1989 Sep; 4(5):511-7. PubMed ID: 2790329
[TBL] [Abstract][Full Text] [Related]
6. Elimination of malignant clonogenic T cells from human bone marrow using chemoimmunoseparation with 2'-deoxycoformycin, deoxyadenosine and an immunotoxin.
Montgomery RB; Kurtzberg J; Rhinehardt-Clark A; Haleen A; Ramakrishnan S; Olsen GA; Peters WP; Smith CA; Haynes BF; Houston LL
Bone Marrow Transplant; 1990 Jun; 5(6):395-402. PubMed ID: 2369680
[TBL] [Abstract][Full Text] [Related]
7. The effect of deoxyadenosine plus deoxycoformycin on replicative and repair synthesis of DNA in human lymphoblasts and isolated nuclei.
Matsumoto SS; Yu J; Yu AL
J Biol Chem; 1988 May; 263(15):7153-8. PubMed ID: 3259231
[TBL] [Abstract][Full Text] [Related]
8. Differential sensitivity of leukemic cells to growth inhibition by deoxyadenosine and deoxycoformycin.
Tanaka M; Kimura K
Tohoku J Exp Med; 1985 Dec; 147(4):331-41. PubMed ID: 3879563
[TBL] [Abstract][Full Text] [Related]
9. Effect of 2'-deoxycoformycin on erythroid, granulocytic, and T-lymphocyte colony growth.
Aye MT; Dunne JV
Blood; 1981 Nov; 58(5):1043-6. PubMed ID: 6975136
[TBL] [Abstract][Full Text] [Related]
10. Studies on the effect of deoxyadenosine on deoxycoformycin-treated myeloid and lymphoid stem cells.
Aye MT; Dunne JV; Yang WC
Blood; 1982 Oct; 60(4):872-6. PubMed ID: 6981441
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
12. Effects of deoxycoformycin in mice. II. Differences between the drug sensitivities and purine metabolizing enzymes of transplantable lymphomas of varying immunologic phenotypes.
Ratech H; Kim J; Asofsky R; Thorbecke GJ; Hirschhorn R
J Immunol; 1984 Jun; 132(6):3077-84. PubMed ID: 6202772
[TBL] [Abstract][Full Text] [Related]
13. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
Yu AL; Bakay B; Kung FH; Nyhan WL
Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
[TBL] [Abstract][Full Text] [Related]
14. Specific immunosuppressive effects of constant infusion of 2'-deoxycoformycin.
Trotta PP; Tedde A; Ikehara S; Pahwa R; Good RA; Balis ME
Cancer Res; 1981 Jun; 41(6):2189-96. PubMed ID: 6972248
[TBL] [Abstract][Full Text] [Related]
15. Potential use of purine nucleosides and enzyme inhibitors for selective depletion of Thy-lymphoblasts from human bone marrow.
Russell NH; Hoffbrand AV; Bellingham AJ
Leuk Res; 1986; 10(3):325-9. PubMed ID: 3081767
[TBL] [Abstract][Full Text] [Related]
16. The effect of deoxycoformycin on bone marrow cells treated with adenosine and deoxyadenosine and hemopoietic growth factors.
Fabian I; Williams Z
Hum Immunol; 1988 Feb; 21(2):81-7. PubMed ID: 3259223
[TBL] [Abstract][Full Text] [Related]
17. Potentiation of growth-inhibitory activity of 9-beta-D-arabinofuranosyladenine by 2'-deoxycoformycin in human cultured cell lines derived from leukemias and lymphomas.
Kuroki Y; Shimoyama M; Inaba S; Hirose M
Jpn J Cancer Res; 1989 May; 80(5):482-9. PubMed ID: 2502523
[TBL] [Abstract][Full Text] [Related]
18. Decreased NAD+ content in human T lymphoblastoid cells treated simultaneously with 2'-deoxycoformycin and 2'-deoxyadenosine.
Koya M; Kanoh T; Uchino H; Ueda K
Nihon Ketsueki Gakkai Zasshi; 1985 Jul; 48(4):1003-11. PubMed ID: 3877388
[No Abstract] [Full Text] [Related]
19. Resistance of pokeweed mitogen-stimulated B cells to inhibition by deoxyadenosine.
Hayward AR
Clin Exp Immunol; 1980 Jul; 41(1):141-9. PubMed ID: 6969149
[TBL] [Abstract][Full Text] [Related]
20. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
